A M García Vicente1, A Soriano Castrejón2, R E Pruneda-González3, G Fernández Calvo3, M M Muñoz Sánchez4, R Álvarez Cabellos5, R Espinosa Aunión6, F Relea Calatayud7. 1. Nuclear Medicine Department, University General Hospital, Ciudad Real, Spain. Electronic address: angarvice@yahoo.es. 2. Nuclear Medicine Department, University General Hospital, Ciudad Real, Spain. 3. Department of Mathematics & IMACI-Institute of Applied Mathematics in Science and Engineering, University of Castilla-La Mancha, Ciudad Real, Spain. 4. Oncology Department, Virgen de la Luz Hospital, Cuenca, Spain. 5. Oncology Department, Virgen de la Salud Hospital, Toledo, Spain. 6. Oncology Department, La Mancha Centro Hospital, Alcázar de San Juan, Ciudad Real, Spain. 7. Pathology Department, University General Hospital, Ciudad Real, Spain.
Abstract
PURPOSE: To explore the relation between tumor kinetic assessed by (18)F-FDG PET and final neoadjuvant chemotherapy (NC) response within a molecular phenotype perspective. MATERIAL AND METHODS: Prospective study included 144 women with breast cancer. All patients underwent a dual-time point (18)F-FDG PET/CT previous to NC. The retention index (RI), between SUV-1 and SUV-2 was calculated. Molecular subtypes were re-grouped in low, intermediate and high-risk biological phenotypes. After NC, all residual primary tumor specimens were histopathologically classified in tumor regression grades (TRG) and response groups. The relation between SUV-1, SUV-2 and RI with the TRG and response groups was evaluated in all molecular subtypes and in accordance with the risk categories. RESULTS: Responder's lesions showed significant greater SUVmax compared to non-responders. The RI value did not show any significant relation with response. Attending to molecular phenotypes, statistical differences were observed with greater SUV for responders having high-risk molecular subtypes. CONCLUSION: Glycolytic tumor characteristics showed a significant correlation with NC response and dependence of risk phenotype.
PURPOSE: To explore the relation between tumor kinetic assessed by (18)F-FDG PET and final neoadjuvant chemotherapy (NC) response within a molecular phenotype perspective. MATERIAL AND METHODS: Prospective study included 144 women with breast cancer. All patients underwent a dual-time point (18)F-FDG PET/CT previous to NC. The retention index (RI), between SUV-1 and SUV-2 was calculated. Molecular subtypes were re-grouped in low, intermediate and high-risk biological phenotypes. After NC, all residual primary tumor specimens were histopathologically classified in tumor regression grades (TRG) and response groups. The relation between SUV-1, SUV-2 and RI with the TRG and response groups was evaluated in all molecular subtypes and in accordance with the risk categories. RESULTS: Responder's lesions showed significant greater SUVmax compared to non-responders. The RI value did not show any significant relation with response. Attending to molecular phenotypes, statistical differences were observed with greater SUV for responders having high-risk molecular subtypes. CONCLUSION: Glycolytic tumor characteristics showed a significant correlation with NC response and dependence of risk phenotype.